Sanofi and Regeneron\'s Libtayo approved on NHS Scotland for cutaneous squamous cell carcinoma

Sanofi and Regeneron's Libtayo approved on NHS Scotland for cutaneous squamous cell carcinoma

04:57 EST 11 Feb 2020 | Pharmafile

Scottish patients will now be able to access Sanofi and Regeneron’s Libtayo (cemiplimab) via the NHS after it became known that the Scottish Medicines Consortium (SMC) awarded conditional approval to the drug as a monotherapy for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) in adults who are not candidates for curative surgery or curative radiation.

The second most prevalent variety of cancer in the UK, there are around 3,000 new diagnoses of CSCC per year in Scotland, with up to 5% of cases progressing to an advanced stage which brings s

read more

More From BioPortfolio on "Sanofi and Regeneron's Libtayo approved on NHS Scotland for cutaneous squamous cell carcinoma"